Characteristics of patients after the first and second dose COVID-19 vaccines
| Characteristics | Total (n=462) | First dose | Second dose | P value |
| Vaccination completed, n (%) | 400 (86.6) | – | – | – |
| Vaccination received, n (%) | – | – | – | |
| Sinovac Life | 251 (54.3) | – | – | – |
| Sinopharm BIBP | 173 (37.5) | – | – | – |
| Others | 38 (8.2) | – | – | – |
| Side effects after any vaccination*, n (%) | 141 (30.5) | – | – | – |
| Gout flare after any vaccination, n (%) | 203 (43.9) | – | – | – |
| Flare ratio, n/N (%) | – | 119/203 (58.6) | 115/203 (56.7) | 0.65 |
| VAS, mean (SD) | – | 5.02 (2.3) | 5.65 (2.3) | 0.04 |
| Without other specific triggers†, n/N (%) | – | 67/119 (56.3) | 61/115 (53.0) | 0.70 |
| Timing of gout flare (days), n/N (%) | – | <0.001 | ||
| Within 1 week | – | 36/119 (30.3) | 22/115 (19.1) | |
| 1 week ~1 month | – | 63/119 (52.9) | 48/115 (41.7) | |
| 1~3 months | – | 20/119 (16.8) | 45/115 (39.1) | |
| Main joint site of gout flare, n/N (%) | – | 0.07 | ||
| First MTP | – | 49/119 (41.2) | 58/115 (50.4) | |
| Ankle and heel | – | 53/119 (44.5) | 51/115 (44.4) | |
| Knee | – | 15/119 (12.6) | 4/115 (3.5) | |
| Wrist | – | 2/119 (1.7) | 2/115 (1.7) |
*Side effects after vaccination includes cold symptoms (fatigue, cough, fever, muscle pain nd headache); wheezing or shortness of breath; nausea, vomiting or diarrhoea; flustered and chest tightness.
†Other specific triggers include cold, exercise, alcohol consumption, diuretic use and purine intake.
VAS, visual analogue score; MTP, metatarsophalangeal.